–News Direct–
By Meg Flippin, Benzinga
Whoever said you cant turn back time hasnt heard of telomere gene therapy. A potentially game-changing field in anti-aging treatment, telomere regeneration involves repairing telomeres or the DNA structures that protect the ends of our chromosomes, similar to caps or shoelaces. Numerous studies have shown that fixing them can extend a persons biological age and even turn back the clock on certain diseases.
As we age, our telomeres become shorter, making us more susceptible to age-related diseases such as osteoporosis, arthritis, heart disease, dementia, Alzheimer's and Parkinson's. Telomeres also affect our appearance. Typically, the longer the telomeres, the younger you look.
Reversing Aging One Telomere At A Time
Repairing Telomeres could prove to be the holy grail of anti-aging treatments, which is why it's a big opportunity. After all, if you could reverse age-related diseases, the benefits could be endless. Thats what Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is hoping proves true with Telomir-1, its potential treatment for age-related conditions.
The company says Telomir-1 is the first novel small molecule to lengthen the DNAs protective telomere caps in order to potentially reverse age-related conditions. The novel molecule which Telomir is currently testing in mice and dogs, with human clinical trials to come later binds to critical metals that wear down telomeres. By limiting the availability of metals and interrupting the enzyme function, Telomir-1 seeks to restore cellular metal homeostasis and reverse a persons biological age. The non-toxic oral therapy provides what the company says is a safe and effective alternative to existing treatments with minimal side effects.
Total Addressable Market and investment Opportunity
That alone is a big market opportunity for Telomir Pharmaceuticals. The longevity and anti-senescence therapy market is valued at $27.11 billion and is projected to reach $44.92 billion by 2031, growing at a CAGR of 6.8% over 2024-2031. Then theres Alzheimer's, where telomere length has also received attention as a biomarker. Nearly seven million Americans suffer from this disease that attacks memory and cognitive functions. By 2050, thats forecast to reach close to 13 million. And let's not forget cancer, another area Telomir-1 could prove effective in fighting. The global oncology market size is projected to reach $521.60 billion by 2033, growing at a CAGR of 8.9% from now until then.
Positive Preclinical Studies & Effectiveness
So far, Telomir is making progress in proving its effectiveness, with early preclinical studies and collaborations with InSilicoTrials indicating Telomir-1's potential efficacy in telomere elongation and age reversal. Positive outcomes in its animal studies include improvements in mobility and cognitive functions, which sets the stage for the company to achieve what it says are significant milestones. Telomir also points to the results of rat and dog studies to be released later this year, which are expected to show Telomir-1s efficacy and safety profile. That may boost investor confidence as it gets one step closer to human trials.
In March, the company presented a scientific poster at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 with data showing Telomir-1 lengthed three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells and mesenchymal stem cells. A subsequent poster presentation at the Global Longevity Federation Conference in Las Vegas further demonstrated that total telomere length was augmented following various Telomir-1 treatments. While more research is needed, these preliminary findings open up the possibility that many diseases long considered inevitable consequences of aging could become avoidable, said Dr. Michael Roizen, special advisor to Telomir. This study further demonstrates our belief that Telomir-1 may have the effect of reversing age through telomere regeneration, enabling the production of more stem cells, essentially allowing an individual to repair oneself.
Canine Opportunity Too
Telomir is focused on bringing its novel telomere therapy to humans, but it is also going after the canine market, aiming to reverse the aging of Americas best friend. Positive preclinical trials have shown that Telomir-1 may have many applications in the veterinary market. That, too, is a big opportunity for Telomir, given that Americans are poised to spend $156 billion on their pets by the end of this year with dogs being the most popular pets.
The world is getting older, but not necessarily healthier. With age-related diseases exploding, finding ways to reverse the impact of time on our bodies is reaching a fever pitch. Telomir may hold the key to anti-aging with Telomir-1. It will be a powerful, revolutionary change. Every country in the world would want to use this product, said Telomir CEO Chris Chapman, if it works on humans. If we can stop the aging process we can stop age-related diseases.
Featured photo by digitale.de on Unsplash.
Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Benzinga
+1 877-440-9464
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/from-pets-to-humans-telomir-pharmaceuticals-nasdaq-telo-holds-the-key-to-extending-life-reversing-aging-257340194
Benzinga
COMTEX_453162910/2655/2024-05-31T09:28:49
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Unique Analyst journalist was involved in the writing and production of this article.